Prognostic Values of the De Ritis Ratio and Other Inflammatory Markers in Patients with Extensive-Stage Small Cell Lung Cancer
Okan Avci1, Cagla Ozcan Umit2, Ahmet Yolcu3, Erdogan Selcuk Seber1, 41Department of Medical Oncology, Namık Kemal University, Tekirdağ, Turkey, 2Department of Internal Medicine, Namık Kemal University, Tekirdağ, Turkey, 3Department of Radiation Oncology, Namık Kemal University, Tekirdağ, Turkey, 4
Objectives: We aimed to evaluate the prognostic significances of the aspartate aminotransferase-to-alanine aminotransferase ratio (the De Ritis ratio) and other some inflammatory markers on survival in extensive-stage small cell lung cancer (ES-SCLC). Methods: A total of 135 patients diagnosed with ES-SCLC in between 2017 and 2020 were included. The pre-treatment values of the De Ritis ratio, the neutrophil-lymphocyte ratio (NLR), the platelet-lymphocyte ratio (PLR), and the pre-treatment levels of gamma-glutamyl transferase (GGT) and lactate dehydrogenase (LDH) were analyzed for their relationship with overall survival (OS). Optimal cutoff values were determined through receiver operating characteristic curves and survival probabilities were analyzed through the Kaplan–Meier method. Multivariate analyses were performed to investigate the prognostic significance of these parameters for ES-SCLC. Results: The median age of the patients at diagnosis was 62.2 (min: 42.5–max: 86.6). The median follow-up time was 8.94±8.02 months. The most common sites of metastasis at admission were bones (33%), followed by the liver (27%), the brain (23%), and the adrenal glands (17%). Median OS was 7.52 months (min: 0.2–max: 50.6). The De Ritis ratio and other inflammatory markers (NLR, PLR, and GGT) were not statistically significantly related with OS (p=0.40; 0.06; 0.29; and 0.49, respectively). Multivariate analyses indicated that only LDH (HR=1.001; p=0.012) was an independent prognostic factor. Conclusion: The De Ritis ratio and other systemic inflammatory markers are not predictive for prognosis in ES-SCLC patients. There is a need for larger prospective studies to investigate the roles of potential biomarker candidates in predicting prognosis in ES-SCLC. Keywords: De Ritis, extensive stage, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, prognosis, small cell lung cancer
Cite This Article
Avci O, Umit C, Yolcu A, Seber E. Prognostic Values of the De Ritis Ratio and Other Inflammatory Markers in Patients with Extensive-Stage Small Cell Lung Cancer. EJMI. 2021; 5(1): 101-106
Corresponding Author: Okan Avci